These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34030027)

  • 1. Cognitive functioning in patients maintained on buprenorphine at peak and trough buprenorphine levels: An experimental study.
    Singh A; Rao R; Chatterjee B; Mishra AK; Kaloiya G; Ambekar A
    Asian J Psychiatr; 2021 Jul; 61():102697. PubMed ID: 34030027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults.
    Arias F; Arnsten JH; Cunningham CO; Coulehan K; Batchelder A; Brisbane M; Segal K; Rivera-Mindt M
    Addict Behav; 2016 Sep; 60():137-43. PubMed ID: 27131800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.
    Soyka M; Hock B; Kagerer S; Lehnert R; Limmer C; Kuefner H
    J Clin Psychopharmacol; 2005 Oct; 25(5):490-3. PubMed ID: 16160628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of psychological symptoms and cognitive functions in patients under maintenance treatment with methadone or buprenorphine, current opioid users and healthy subjects.
    Nikraftar NS; Feyzi YF; Ramzani F; Nikbakht-Zadeh M; Amini M; Arezoomandan M; Shiehmorteza M; Arezoomandan R
    Asian J Psychiatr; 2021 Apr; 58():102603. PubMed ID: 33621923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive functions in patients on buprenorphine maintenance for opioid dependence: A comparative study with three matched control groups.
    Saroj R; Ghosh A; Subodh BN; Nehra R; Mahintamani T; Rana DK; Basu D
    Asian J Psychiatr; 2020 Oct; 53():102181. PubMed ID: 32526693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial.
    Ahmadi J; Sefidfard Jahromi M
    Subst Use Misuse; 2018 Jan; 53(2):286-289. PubMed ID: 29148881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.
    Mattick RP; Ali R; White JM; O'Brien S; Wolk S; Danz C
    Addiction; 2003 Apr; 98(4):441-52. PubMed ID: 12653814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function.
    Shmygalev S; Damm M; Weckbecker K; Berghaus G; Petzke F; Sabatowski R
    Drug Alcohol Depend; 2011 Sep; 117(2-3):190-7. PubMed ID: 21353749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
    Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
    JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.